- Home
- CTMX vs BOWN Comparison
CTMX vs BOWN Comparison
Compare CTMX & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BOWN
- Stock Information
- Founded
- CTMX 2008
- BOWN 2023
- Country
- CTMX United States
- BOWN United States
- Employees
- CTMX N/A
- BOWN N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BOWN
- Sector
- CTMX Health Care
- BOWN
- Exchange
- CTMX Nasdaq
- BOWN Nasdaq
- Market Cap
- CTMX 60.1M
- BOWN N/A
- IPO Year
- CTMX 2015
- BOWN 2023
- Fundamental
- Price
- CTMX $1.09
- BOWN $12.46
- Analyst Decision
- CTMX Buy
- BOWN
- Analyst Count
- CTMX 5
- BOWN 0
- Target Price
- CTMX $5.52
- BOWN N/A
- AVG Volume (30 Days)
- CTMX 1.7M
- BOWN 55.3K
- Earning Date
- CTMX 05-12-2025
- BOWN 01-01-0001
- Dividend Yield
- CTMX N/A
- BOWN N/A
- EPS Growth
- CTMX N/A
- BOWN N/A
- EPS
- CTMX 0.38
- BOWN 0.32
- Revenue
- CTMX $138,103,000.00
- BOWN N/A
- Revenue This Year
- CTMX N/A
- BOWN N/A
- Revenue Next Year
- CTMX N/A
- BOWN N/A
- P/E Ratio
- CTMX $2.89
- BOWN $35.85
- Revenue Growth
- CTMX 36.45
- BOWN N/A
- 52 Week Low
- CTMX $0.40
- BOWN $2.71
- 52 Week High
- CTMX $2.81
- BOWN $19.77
- Technical
- Relative Strength Index (RSI)
- CTMX 77.87
- BOWN 65.47
- Support Level
- CTMX $0.63
- BOWN $9.11
- Resistance Level
- CTMX $1.04
- BOWN $12.57
- Average True Range (ATR)
- CTMX 0.10
- BOWN 2.53
- MACD
- CTMX 0.04
- BOWN 0.08
- Stochastic Oscillator
- CTMX 82.43
- BOWN 34.03
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.